2016
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.Peer-Reviewed Original Research027 Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome
Walker S, Wang C, Walradt T, Hong B, Tanner J, Levinsohn J, Goh G, Subtil A, Lessin S, Heymann W, Vonderheid E, King B, Lifton R, Choi J. 027 Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Journal Of Investigative Dermatology 2016, 136: s5. DOI: 10.1016/j.jid.2016.02.051.Peer-Reviewed Original ResearchLymphocytic variant hypereosinophilic syndromeHypereosinophilic syndromeFunction STAT3 mutationsSTAT3 mutations
2015
Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome
Walker S, Wang C, Walradt T, Hong BS, Tanner JR, Levinsohn JL, Goh G, Subtil A, Lessin SR, Heymann WR, Vonderheid EC, King BA, Lifton RP, Choi J. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 2015, 127: 948-951. PMID: 26702067, PMCID: PMC4760095, DOI: 10.1182/blood-2015-06-654277.Peer-Reviewed Original Research